<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943356</url>
  </required_header>
  <id_info>
    <org_study_id>TEDQOL</org_study_id>
    <nct_id>NCT02943356</nct_id>
  </id_info>
  <brief_title>Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction</brief_title>
  <official_title>Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study to evaluate the effect of Tadalafil 5mg once daily on Erectile
      Dysfunction and QOL in Andropause patients with Erectile Dysfunction.

      Patients will be observed for 8weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on SF-12 Score from baseline to week 8</measure>
    <time_frame>week 0 to week 8</time_frame>
    <description>The comparison of change of Quality of Live at baseline and 8 week (SF-12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on SF-12 Score from baseline to week 4</measure>
    <time_frame>week 0 to week 4</time_frame>
    <description>The comparison of change of Quality of Life at baseline and 4 week (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on bioimpedance Analysis from baseline to week 8</measure>
    <time_frame>week 0 to week 8</time_frame>
    <description>The comparison of change of bioimpedance Analysis at baseline and 8 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on IIEF-5 Score from baseline to week 4, week 8</measure>
    <time_frame>week 0 to week 4, week 8</time_frame>
    <description>The comparison of score at baseline, 4 week and 8 week (IIEF-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on free radical from baseline to week 4, week 8</measure>
    <time_frame>week 0 to week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Andropause</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Tadalafil for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Patients will be treated with Tadalafil for 8 weeks</description>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Above 35 years men

          2. Approving ADAM questionnaire and andropause patients with symptoms under contents

             ; easily fatigue, decreased sexual desire, general weakness, decreasing memory ect.

          3. Patient with Erectile Dysfunction above 6 months

          4. International Index of Erectile Function(IIEF-5) score under 21

          5. Voluntarily one want to treatment with Tadalafil 5 mg daily

          6. Voluntarily one agree this study and write informed consent

        Exclusion Criteria:

          1. Persons who have taken PDE-5 inhibitor within last one month for Erectile Dysfunction

          2. Persons who taken testosterone treatment within last one month

          3. Persons who be history of Myocardiac infarction

          4. The history of taken organic nitrate drug

          5. The history of cardiovascular disease

               -  In myocardial infarction within the last 90 days was now

               -  Unstable angina or angina pectoris during intercourse that occurred

               -  New York Heart Association Class 2 during the last six months or more sever
                  cardiac failure

               -  Uncontrolled arrythmia, hypotension(〈90/50mmHg), or uncontrolled blood
                  pressure(〉170/100mmHg)

               -  Persons who have a stroke within the last six months

          6. Persons who have degrative retinal disease including Pigmentary retinites

          7. Formerly persons who have one eye blindness by Artery anterior ischemic optic
             neuropathy with or without taking PDE5 inhibitor.

          8. Persons who use inhibitor or agonist drug f Hepatic cytochrome P4503A4

          9. Persons who use alpha antagonist add antihypertensive drug

         10. Moderate liver or kidney failure

         11. Major psychiatric or personality disorder

         12. Persons have phobia trial drug

         13. Persons have invasive treatment of prostate gland

         14. Congenital anomaly of penis

         15. Galactose, Lactose, Glucose intolerance patient

         16. Research coordinators who are deemed unfit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keun-Sang Yum, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uijeongbu St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keun-Sang Yum, M.D., PhD</last_name>
    <phone>8231-820-3179</phone>
    <email>yks6303@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uijeongbu St.Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Sang Yum, M.D., PhD</last_name>
      <phone>82-31-820-3179</phone>
      <email>yks6303@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Keun-Sang Yum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

